Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded down 0.1% during trading on Wednesday . The stock traded as low as $28.20 and last traded at $28.26. 5,438,659 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 38,337,391 shares. The stock had previously closed at $28.30.
Analyst Ratings Changes
A number of equities analysts have commented on the company. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Barclays increased their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.54.
Get Our Latest Analysis on Pfizer
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.89%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.
Institutional Investors Weigh In On Pfizer
Several institutional investors have recently made changes to their positions in PFE. Norges Bank acquired a new position in Pfizer in the fourth quarter valued at about $2,129,927,000. Wellington Management Group LLP increased its stake in Pfizer by 4.9% in the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Pfizer by 13.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after buying an additional 8,298,920 shares in the last quarter. Finally, Swedbank AB acquired a new position in shares of Pfizer during the first quarter worth $172,902,000. 68.36% of the stock is currently owned by institutional investors.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- Industrial Products Stocks Investing
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- With Risk Tolerance, One Size Does Not Fit All
- Introduction to Fibonacci Retracement Levels
- What is Put Option Volume?
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.